Aridis Pharmaceuticals (ARDS) Competitors $0.0001 0.00 (0.00%) As of 05/1/2025 02:15 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ARDS vs. NAVB, SCPS, EVLO, SMFL, CMRA, GNCAQ, GNCA, STAB, AMPE, and EFTRShould you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Smart for Life (SMFL), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Aridis Pharmaceuticals vs. Navidea Biopharmaceuticals Scopus BioPharma Evelo Biosciences Smart for Life Comera Life Sciences Genocea Biosciences Genocea Biosciences Statera Biopharma Ampio Pharmaceuticals eFFECTOR Therapeutics Aridis Pharmaceuticals (NASDAQ:ARDS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations. Does the MarketBeat Community prefer ARDS or NAVB? Aridis Pharmaceuticals received 122 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 61.00% of users gave Aridis Pharmaceuticals an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformAridis PharmaceuticalsOutperform Votes12261.00% Underperform Votes7839.00% Navidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes85100.00% Do insiders & institutionals believe in ARDS or NAVB? 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to ARDS or NAVB? In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Aridis Pharmaceuticals Neutral Navidea Biopharmaceuticals Neutral Which has better valuation & earnings, ARDS or NAVB? Navidea Biopharmaceuticals has lower revenue, but higher earnings than Aridis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAridis Pharmaceuticals$3.09M0.00-$30.37MN/AN/ANavidea Biopharmaceuticals$8.13K8.62-$15.18MN/AN/A Is ARDS or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Aridis PharmaceuticalsN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Which has more volatility and risk, ARDS or NAVB? Aridis Pharmaceuticals has a beta of 9.88, meaning that its stock price is 888% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. SummaryAridis Pharmaceuticals beats Navidea Biopharmaceuticals on 5 of the 8 factors compared between the two stocks. Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDS vs. The Competition Export to ExcelMetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5,000.00$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / Sales0.00241.49397.62103.30Price / CashN/A65.8538.1834.62Price / BookN/A6.486.734.25Net Income-$30.37M$143.41M$3.22B$248.18M7 Day PerformanceN/A2.58%1.38%1.03%1 Month PerformanceN/A5.00%2.79%2.70%1 Year PerformanceN/A-3.72%15.41%4.05% Aridis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.8%$5,000.00$3.09M0.0030NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-98.1%$20,000.00$8,126.000.0010Analyst ForecastSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/A-98.9%$9,000.00N/A0.00120Options VolumeNews CoverageSMFLSmart for LifeN/A$0.00+233.3%N/A-100.0%$7,000.00$11.11M0.00110Gap UpCMRAComera Life SciencesN/AN/AN/A-99.7%$6,000.00$1.00M0.002Gap DownGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070STABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00-96.3%N/A-99.8%$1,000.00N/A0.0020Analyst ForecastHigh Trading VolumeEFTReFFECTOR TherapeuticsN/A$0.00flatN/A-100.0%$1,000.00$3.55M0.0010 Related Companies and Tools Related Companies NAVB Alternatives SCPS Alternatives EVLO Alternatives SMFL Alternatives CMRA Alternatives GNCAQ Alternatives GNCA Alternatives STAB Alternatives AMPE Alternatives EFTR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARDS Stock Free ARDS Stock Alerts